Neville Rodie & Shaw’s Bristol-Myers Squibb BMY Stock Holding History

Neville Rodie & Shaw’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27M	Sell	39,489 -50	-0.1%	-$2.87K	0.15%	91
2026 Q1	$2.4M	Sell	39,539 -15	-0%	-$874	0.17%	82
2025 Q4	$2.13M	Buy	39,554 +750	+2%	+$36.1K	0.15%	88
2025 Q3	$1.75M	Hold	38,804	–	–	0.13%	97
2025 Q2	$1.8M	Sell	38,804 -11,285	-23%	-$554K	0.13%	96
2025 Q1	$3.06M	Sell	50,089 -500	-1%	-$29.1K	0.24%	74
2024 Q4	$2.86M	Buy	50,589 +10,400	+26%	+$581K	0.21%	79
2024 Q3	$2.08M	Sell	40,189 -7,300	-15%	-$342K	0.15%	92
2024 Q2	$1.97M	Sell	47,489 -52,032	-52%	-$2.33M	0.15%	93
2024 Q1	$5.4M	Sell	99,521 -9,950	-9%	-$507K	0.41%	57
2023 Q4	$5.62M	Sell	109,471 -45,082	-29%	-$2.37M	0.46%	50
2023 Q3	$8.97M	Sell	154,553 -1,912	-1%	-$117K	0.8%	35
2023 Q2	$10M	Sell	156,465 -1,125	-0.7%	-$75.4K	0.86%	32
2023 Q1	$10.9M	Buy	157,590 +2,458	+2%	+$173K	0.99%	28
2022 Q4	$11.2M	Buy	155,132 +2,550	+2%	+$192K	1.05%	31
2022 Q3	$10.8M	Sell	152,582 -3,400	-2%	-$247K	1.07%	27
2022 Q2	$12M	Buy	155,982 +745	+0.5%	+$56.7K	1.08%	30
2022 Q1	$11.5M	Buy	155,237 +75	+0%	+$5.04K	0.85%	35
2021 Q4	$9.67M	Sell	155,162 -8,950	-5%	-$525K	0.69%	42
2021 Q3	$9.71M	Buy	164,112 +812	+0.5%	+$53.5K	0.75%	40
2021 Q2	$10.9M	Sell	163,300 -194	-0.1%	-$12.7K	0.84%	37
2021 Q1	$10.3M	Buy	163,494 +3,265	+2%	+$203K	0.86%	36
2020 Q4	$9.94M	Sell	160,229 -9,175	-5%	-$564K	0.86%	35
2020 Q3	$10.2M	Sell	169,404 -2,534	-1%	-$153K	0.96%	36
2020 Q2	$10.1M	Sell	171,938 -5,471	-3%	-$327K	1.04%	29
2020 Q1	$9.89M	Buy	177,409 +4,150	+2%	+$254K	1.2%	23
2019 Q4	$11.1M	Buy	173,259 +94,799	+121%	+$5.43M	1.09%	27
2019 Q3	$3.98M	Sell	78,460 -2,100	-3%	-$98.7K	0.42%	65
2019 Q2	$3.65M	Sell	80,560 -4,695	-6%	-$219K	0.39%	72
2019 Q1	$4.07M	Buy	85,255 +275	+0.3%	+$13.7K	0.43%	65
2018 Q4	$4.42M	Sell	84,980 -3,651	-4%	-$196K	0.54%	57
2018 Q3	$5.5M	Buy	88,631 +106	+0.1%	+$6.29K	0.54%	58
2018 Q2	$4.9M	Sell	88,525 -5,398	-6%	-$292K	0.52%	61
2018 Q1	$5.94M	Sell	93,923 -915	-1%	-$58.9K	0.66%	51
2017 Q4	$5.81M	Sell	94,838 -1,600	-2%	-$100K	0.61%	58
2017 Q3	$6.15M	Buy	96,438 +500	+0.5%	+$29.2K	0.69%	54
2017 Q2	$5.35M	Sell	95,938 -1,080	-1%	-$58.8K	0.61%	59
2017 Q1	$5.28M	Sell	97,018 -4,425	-4%	-$243K	0.6%	58
2016 Q4	$5.93M	Sell	101,443 -4,282	-4%	-$234K	0.7%	49
2016 Q3	$5.7M	Buy	105,725 +2,000	+2%	+$128K	0.67%	52
2016 Q2	$7.63M	Sell	103,725 -1,565	-1%	-$111K	0.91%	31
2016 Q1	$6.73M	Buy	105,290 +1,150	+1%	+$72.5K	0.82%	36
2015 Q4	$7.16M	Buy	104,140 +50	+0%	+$3.3K	0.86%	35
2015 Q3	$6.16M	Sell	104,090 -8,014	-7%	-$508K	0.76%	42
2015 Q2	$7.46M	Sell	112,104 -14,577	-12%	-$961K	0.82%	33
2015 Q1	$8.17M	Buy	126,681 +3,825	+3%	+$239K	0.85%	33
2014 Q4	$7.25M	Buy	122,856 +625	+0.5%	+$35.2K	0.73%	41
2014 Q3	$6.26M	Buy	122,231 +27,690	+29%	+$1.38M	0.62%	50
2014 Q2	$4.59M	Buy	94,541 +7,398	+8%	+$365K	0.46%	67
2014 Q1	$4.53M	Sell	87,143 -2,504	-3%	-$133K	0.49%	65
2013 Q4	$4.76M	Sell	89,647 -3,100	-3%	-$158K	0.52%	62
2013 Q3	$4.29M	Sell	92,747 -900	-1%	-$39.5K	0.5%	59
2013 Q2	$4.18M	Buy	+93,647	New	+$4.07M	0.51%	56

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Neville Rodie & Shaw's BMY Position: Q2 2026 in Review

Neville Rodie & Shaw reduced its Bristol-Myers Squibb (BMY) stake by 0.13% in Q2 2026, selling an estimated $2.87K and leaving 39,489 shares worth $2.27M. The position accounts for 0.15% of the portfolio, ranked #91.

Neville Rodie & Shaw first reported a position in BMY in Q2 2013 and has held it in 53 quarters since. The position peaked at $12M in Q2 2022. 1,158 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Neville Rodie & Shaw held 39,489 shares of Bristol-Myers Squibb worth $2.27M as of Q2 2026.
Neville Rodie & Shaw sold 50 Bristol-Myers Squibb shares in Q2 2026, an estimated $2.87K.
Bristol-Myers Squibb made up 0.15% of Neville Rodie & Shaw's portfolio in Q2 2026, its #91 holding.
Neville Rodie & Shaw first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 53 quarters since.
Neville Rodie & Shaw's Bristol-Myers Squibb position peaked at $12M in Q2 2022.
1,158 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Neville Rodie & Shaw's 13F filing for Q2 2026, filed 6 Jul 2026.